AMENDMENTS TO THE CLAIMS

1. (Currently amended) An immunogenic recombinant antibody designed for immunization of primates wherein the antibody is an IgG1 antibody wherein a constant region of said IgG1 antibody comprises a constant region of an IgG2a subtype amino acid sequence and a hamster or primate glycosylation.

2. (Currently amended) The antibody according to claim 1 that contains an epitope specific for a tumor associated antigen or specific for a fragment ~~fragments thereof~~of the tumor associated antigen.

3. (Currently amended) The antibody according to claim 1 that contains a mimotope triggering immune response specific for a tumor associated antigen or specific for a fragment~~fragments thereof~~ of the tumor associated antigen.

4. (Previously Presented) The antibody according to claim 1 or 3 that contains an Ep-CAM mimotope.

5. (Currently amended) The antibody according to claim 1 or claim 3 that contains a Lewis-y ~~isotope~~mimotope.

6. (Previously Presented) The antibody according to claim 4, which is a chimeric or humanized antibody.

7. (Previously Presented) The antibody according to claim 4, which is an anti-idiotypic antibody.

8. (Previously Presented) The antibody according to claim 7, which is directed against the idiotype of an antibody specific for a tumor associated antigen.

9. (Currently amended) The antibody according to claim[[ ]] 2 or 3, wherein the antigen is selected from the group consisting of peptides or proteins, carbohydrates, and glycolipids.

10. (Previously Presented) The antibody according to claim 4, which is a bi-isotopic antibody.

11. (Canceled)

12. (Previously Presented) The antibody according to claim 1, wherein the IgG2a subtype amino acid sequence is contained in at least one of the regions selected from the group consisting of the CH1, hinge, CH2 and CH3 regions.

13. (Currently amended) The antibody according to claim 1, which is an anti-idiotypic antibody to monoclonal antibodies produced by hybridomas deposited as ATCC HB 9324 or ATCC HB 9347.

14. (Previously Presented) A vaccine comprising an antibody according to claim 1 in a pharmaceutical formulation.

15. (Previously Presented) A vaccine according to claim 14, wherein the pharmaceutical formulation contains an adjuvant.

16. (Previously Presented) A multicistronic antibody expression construct for producing an antibody according to claim 1 in a CHO or HEK293 expression system, which contains at least a nucleotide sequence encoding a kappa light chain and a nucleotide sequence encoding a gamma heavy chain, wherein at least one of the nucleotide sequences encoding a kappa light chain or gamma heavy chain comprises a nucleotide sequence encoding at least a part of a murine IgG2a subtype amino acid sequence, and at least two IRES elements.

17. (Previously Presented) The antibody expression construct of claim 16, wherein the nucleotide sequence encoding at least the part of the murine IgG2a subtype amino acid sequence is ligated into the nucleotide sequence encoding the kappa light chain or the gamma heavy chain by one of insertion or substitution techniques.

18. (Previously Presented) A vector comprising a promotor, an antibody-expression construct of claim 16 and a transcription termination sequence.

19. (Previously Presented) The vector according to claim 18, wherein one of the IRES sequences is attenuated by an inserted sequence that downregulates the entry of the ribosomes.

20. (Previously Presented) A CHO host cell or a HEK 293 transformed with vector according to claim 18.

21. (Previously Presented) A method of producing an antibody according to claim 1 comprising

- transforming a CHO or HEK293 host cell with a multicistronic antibody-expression construct containing at least a nucleotide sequence encoding a kappa light chain and a nucleotide sequence encoding a gamma heavy chain, wherein at least one of the nucleotide sequences comprises a nucleotide sequence encoding at least a part of a murine IgG2a subtype amino acid sequence, and at least two IRES elements, and

-expressing said nucleotide sequences under the control of a single CMV promoter to produce an intact antibody,

-transcription of a single RNA comprising protein sub-units and selection marker.

22. (Previously Presented) The method according to claim 21, wherein one of the IRES elements is an attenuated IRES sequence, which attenuated IRES sequence downregulates the expression of a quantitative selection marker operably linked thereto.

23. (Previously Presented) The method according to claim 22, wherein the selection marker sequence is a gene encoding dihydrofolate reductase.

24. (Previously Presented) The method according to claim 21, wherein the nucleotide sequences are expressed by culturing transfected CHO cells that are deficient in dihydrofolate reductase, preferably in the presence of a selective methotrexate concentration ranging from 1 to 10 μmol/l.

25. (Previously Presented) The method according to claim 21, wherein the nucleotide sequence encoding the kappa chain and a nucleotide sequence encoding the gamma chain are linked by an IRES sequence.

26. (Previously Presented) The method according to claim 21, producing the kappa light chain and gamma heavy chain in about equimolar quantity.

27. (Previously Presented) The method according to claim 21, producing an antibody concentration of at least lμg/ml, preferably 5-50 μg/ml.

28. (Previously Presented) The method according to claim 21, wherein the host cell is cultured in a serum free medium.

29. (Previously Presented) The antibody according to claim 2, wherein said antigen is a carbohydrate.

30. (Previously Presented) The antibody according to claim 29, wherein said carbohydrate is a member selected from the group consisting ofLewis-y, Sialyl-Tn, and Globo H.

31. (Currently Amended) The antigen of claim 9 wherein said antigen comprises one or more peptides or proteins selected from the group consisting of EpCAM, NCAM, CEA and T-cell peptides, and wherein said carbohydrates are selected from the group consisting of Lewis-y, Sialyl Tn, and ~~Globe~~ Globo H, and wherein said glycolipids are selected from the group consisting of GD2, GD3, and GM2.

32. (Currently Amended) The antigen of claim 9 wherein said antigen comprises one or more carbohydrates selected from the group consisting of Lewis-y, Sialyl Tn, and ~~Globe~~ Globo H.

33. (Previously Presented) The antigen of claim 9 wherein said antigen comprises one or more glycolipids selected from the group consisting of GD2, GD3, and GM2.

34. (New) An immunogenic recombinant antibody fragment comprising either SEQ ID NO: 3 or SEQ ID NO: 4 and hamster or primate glycosylation.